Although the prevalence of bicuspid aortic valve (BAV) is only 0.5-1% in children, it accounts for about half of aortic valve replacements (AVRs) for aortic valve stenosis (AS). These findings illustrate that valve remodelling occurs more frequently and more rapidly on bicuspid than on tricuspid aortic valves (TAVs). During their lifetime, most subjects with a BAV develop aortic valve dysfunction, mostly AS, whereas only 1% remains with a normal valve function.
Individuals with a BAV, however, develop AS one or two decades earlier than those with a TAV and their lifetime risk of AVR is around 50% ( Table 1) . In this issue of the journal, Huntley et al. 3 present an elegant study in which they compared age-matched cohorts of 198 BAV stenosis and 198 TAV stenosis patients. The authors found that, at a given age, patients with TAV stenosis have higher prevalence of cardiovascular risk factors, greater degree of cardiac impairment and worse survival after AVR compared to those with BAV stenosis ( Table 1) .
Genetic susceptibility to AS in BAV vs. TAV
The mutations that have been identified in families with BAV are in the NOTCH1 and GATA5 genes 2,4 ( Table 1 ). The NOTCH1 mutations are associated with both BAV phenotype and derepression of aortic valve calcium deposition. Hence, these mutations not only predispose to the development of a BAV but they also promote valve mineralization later in life, therefore exacerbating the risk of developing AS. In subjects with TAV, studies using a candidate gene approach have identified several genes ( Table 1) . However, these associations still need to be confirmed in larger samples. Recent large studies using a Mendelian randomization design have identified the single-nucleotide polymorphism (rs10455872) at the LPA gene locus as the only genome-wide significant single-nucleotide polymorphism associated with the presence of aortic valve calcification and clinical AS. the most powerful risk factor of AS, i.e. age. The cohorts were also well matched with respect to sex, which has been shown to have an important effect on the pathobiology and outcome of AS. 2, 6 The prevalence of cardiovascular risk factors such as obesity, diabetes, hypertension, and hypercholesterolaemia as well as that of atherosclerotic diseases such as coronary artery disease and peripheral vascular disease were much higher in the TAV stenosis cohort than in the BAV stenosis cohort, despite similar age and sex distribution in both cohorts. 3 The most striking difference between the two cohorts was for diabetes, which prevalence was 2.4 higher in TAV (46 vs. 19%). Obesity, metabolic syndrome, and diabetes are among the risk factors that exhibit the strongest association with AS incidence, progression, and outcomes. 7, 8 Furthermore, these cardiometabolic risk factors are also associated with higher risk of structural valve deterioration following AVR with a bioprosthesis. 9 Hypertension has also been reported to have an important effect on the pathophysiology and outcomes of AS both prior and after AVR.
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The marked over-representation of cardiovascular risk factors in the TAV cohort vs. the BAV cohort after age matching 3 provides support to the concept that, in middle-age TAV subjects, the progression rate, and clinical outcome of calcific AS are, in large part, driven by cardiometabolic risk factors ( Table 1) . In BAV patients, the aforementioned genetic factors as well as mechanical factors related to the BAV configuration (i.e. increased mechanical stress on valve leaflets and turbulent transvalvular flow) likely have a predominant contribution to the pathogenesis of AS and these factors may occult-or Table 1) .
In their study, Hunter et al. 3 did not report the prevalence of metabolic syndrome and Lp(a). One would expect that plasma levels of Lp(a), a potential causal factor of calcific AS, would be higher in the TAV cohort than in the BAV cohort. The differences in the baseline risk profile between the TAV and BAV stenosis cohorts largely explain the worse cardiac function and lower survival rates observed in the TAV cohort ( Table 1) . 3 Interestingly, the 5-year survival rate (79%) in the BAV cohort was comparable to the expected survival in the general population (86%), whereas in the TAV cohort, survival was substantially lower (61%). In the multivariable analysis, the Charlson comorbidity index but not the aortic valve phenotype was associated with increased risk of mortality after AVR. This is consistent with the fact that differences in outcomes between TAV and BAV are, in large part, related to differences in baseline risk profile and comorbidities ( Table 1) . Compared with subjects with TAV, those with BAV have larger aortic annulus and thus lower prevalence of small prosthetic valves and ensuing prosthesis-patient mismatch following AVR. In this study, 3 prosthesis-patient mismatch was indeed more frequent in TAV than in BAV patients (37 vs. 25%; P = 0.019) and was strongly and independently associated with increased risk of mortality. This finding may also contribute to explain the worse survival observed in TAV vs. BAV patients. This also further emphasizes the importance of avoiding prosthesis-patient mismatch in patients with severe AS undergoing AVR.
Conclusion
If you are born with a normal TAV, you likely need to have cardiovascular risk factors such as metabolic syndrome, diabetes, hypertension, dyslipidaemia, or high Lp(a), to develop AS at a young or middle age. On the other hand, if you are born with a BAV, you have a high likelihood to develop AS at relatively young age, even in the absence of any of these risk factors. As expected, BAV patients more frequently have concomitant aortopathy, which does not appear to alter their prognosis after AVR. On the other hand, these patients have larger aortic annulus and thus lower risk of prosthesis-patient mismatch following AVR, compared to TAV patients. This difference further contributes to the better survival of BAV vs. TAV patients after AVR. Future interventional studies should focus on aggressive cardiovascular risk factor management to improve outcomes after AVR, particularly in the subset of patients with a TAV. 
